Piramal Pharma Solutions has opened a microbiology laboratory at its sterile injectable plant in Lexington, Kentucky. The project advances an 85 million dollar expansion.

The new space triples testing floor area. It targets a 50 per cent cut in product release turnaround times.

Regulators cleared routine Good Manufacturing Practice work on September 11, 2026. Conditional approval for the adjoining sterility suite followed soon after. The lab unit forms the first operational phase of the multi-year capital program.

Engineers reconfigured the Lexington site to handle higher volumes of sterile drug products for clinical and commercial use. The upgrade adds three biosafety cabinets for concurrent testing. It also consolidates all incubation equipment into a single footprint.

A dedicated Grade C cleanroom suite houses a Grade A sterility testing isolator. That setup replaces a non-classified zone. It doubles testing throughput by running open and closed filtration on multiple batches at once. Built-in sample pass-throughs connect manufacturing suites directly to analytical benches.

Global sterile injectable manufacturing faces capacity crunches, particularly for antibody-drug conjugates, peptides and high-potency small molecules. Bringing microbiology and sterility testing in-house cuts sample transport delays. It also lowers contamination risks.

Faster batch clearance gives the company an edge over Asian contract development and manufacturing rivals tied strictly to domestic facilities. Shorter release cycles also help pharmaceutical clients. They trim inventory holding costs and speed market access.

Indian contract manufacturers continue to buy and upgrade assets in North America and Europe to stay close to clinical sponsors. Piramal Pharma Limited trades in Mumbai on both the BSE and the National Stock Exchange of India.

Source link